Benjamin Levy on Advances in Diagnosing Lung Cancer
Benjamin Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses recent advances in the detection and diagnosis of lung cancer.
Benjamin Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses recent advances in the detection and diagnosis of lung cancer.
Lung cancer has traditionally been diagnosed using tissue biopsies, though over the past two years, Levy says research shows diagnoses can be achieved early through a simple blood test. These blood samples contain cell-free DNA (cfDNA) that is shed from the tumor and may provide useful biomarkers or molecular drivers.
Similar to tissue biopsies, molecular profiling can also be performed on blood samples, Levy adds.
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
September 19th 2024The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.
